1.周围神经病理性疼痛诊疗中国专家共识 [J]. 中国疼痛医学杂志, 2020, 26 (05): 321-328.
2.van Hecke O, et al. Neuropathic pain in the general population: a systematic review of epidemiological studies. Pain. 2014 Apr;155(4):654-662.
3.Colloca L, et al. Neuropathic pain. Nat Rev Dis Primers. 2017 Feb 16;3:17002.
4.Inoue S, et al. The prevalence and impact of chronic neuropathic pain on daily and social life: A nationwide study in a Japanese population. Eur J Pain. 2017 Apr;21(4):727-737.
5.Yang M, et al. Suboptimal Treatment of Diabetic Peripheral Neuropathic Pain in the United States. Pain Med. 2015 Nov;16(11):2075-83.
6.杜成欣,等.神经病理性疼痛患者的自我管理:定义、要素与展望 [J]. 中国慢性病预防与控制, 2023, 31 (09): 702-705.
7.Kim JY, et al. Mirogabalin: could it be the next generation gabapentin or pregabalin? Korean J Pain. 2021 Jan 1;34(1):4-18.
8.Domon Y, et al. Binding characteristics and analgesic effects of mirogabalin, a novel ligand for the α2δ subunit of voltage-gated calcium channels[J]. Journal of Pharmacology and Experimental Therapeutics, 2018, 365(3): 573-582.
9.Chincholkar M. Gabapentinoids: pharmacokinetics, pharmacodynamics and considerations for clinical practice. Br J Pain. 2020 May;14(2):104-114.
10.Baba M, M et al. Mirogabalin for the treatment of diabetic peripheral neuropathic pain: A randomized, double-blind, placebo-controlled phase III study in Asian patients. J Diabetes Investig. 2019 Sep;10(5):1299-1306.
11.Baba M, et al. Long-term safety and efficacy of mirogabalin in Asian patients with diabetic peripheral neuropathic pain. J Diabetes Investig. 2020 May;11(3):693-698.
12.Guo X, et al. A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled 14-Week Study of Mirogabalin in Chinese Patients with Diabetic Peripheral Neuropathic Pain. Pain Ther. 2024 Aug;13(4):937-952.
13.Baba M, et al. Mirogabalin in Japanese Patients with Renal Impairment and Pain Associated with Diabetic Peripheral Neuropathy or Post-Herpetic Neuralgia: A Phase III, Open-Label, 14-Week Study. J Pain Res. 2020 Jul 17;13:1811-1821.